The significant outperformance of Vertex Pharmaceuticals over the past 15 years, with an average annual return of 20.02%, highlights the company's strong growth trajectory and its potential for continued success. This historical performance, coupled with a current market capitalization of $112.02 billion, suggests a positive outlook for VRTX in the short term, as investors may be drawn to its proven track record of generating substantial returns.